268 related articles for article (PubMed ID: 7686824)
1. [Mouse neurovirulence of antigenic chimeras (type I/II) of polioviruses].
Dai C
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Feb; 15(1):34-8. PubMed ID: 7686824
[TBL] [Abstract][Full Text] [Related]
2. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I.
Murray MG; Bradley J; Yang XF; Wimmer E; Moss EG; Racaniello VR
Science; 1988 Jul; 241(4862):213-5. PubMed ID: 2838906
[TBL] [Abstract][Full Text] [Related]
4. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
Kohara M; Abe S; Yoshioka I; Nomoto A
Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
[TBL] [Abstract][Full Text] [Related]
5. Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies.
La Monica N; Kupsky WJ; Racaniello VR
Virology; 1987 Dec; 161(2):429-37. PubMed ID: 2825415
[TBL] [Abstract][Full Text] [Related]
6. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
7. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.
Martin A; Wychowski C; Couderc T; Crainic R; Hogle J; Girard M
EMBO J; 1988 Sep; 7(9):2839-47. PubMed ID: 2460345
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.
Couderc T; Hogle J; Le Blay H; Horaud F; Blondel B
J Virol; 1993 Jul; 67(7):3808-17. PubMed ID: 8389907
[TBL] [Abstract][Full Text] [Related]
9. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.
La Monica N; Meriam C; Racaniello VR
J Virol; 1986 Feb; 57(2):515-25. PubMed ID: 3003384
[TBL] [Abstract][Full Text] [Related]
10. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.
Martin A; Benichou D; Couderc T; Hogle JM; Wychowski C; Van der Werf S; Girard M
Virology; 1991 Feb; 180(2):648-58. PubMed ID: 1846492
[TBL] [Abstract][Full Text] [Related]
11. Retrograde transport of intact poliovirus through the axon via the fast transport system.
Ohka S; Yang WX; Terada E; Iwasaki K; Nomoto A
Virology; 1998 Oct; 250(1):67-75. PubMed ID: 9770421
[TBL] [Abstract][Full Text] [Related]
12. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
13. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of poliomyelitis: what we don't know.
Nathanson N
Adv Virus Res; 2008; 71():1-50. PubMed ID: 18585526
[TBL] [Abstract][Full Text] [Related]
15. Potential use of poliovirus as a vector.
Girard M; Martin A; van der Werf S
Biologicals; 1993 Dec; 21(4):371-7. PubMed ID: 8024753
[TBL] [Abstract][Full Text] [Related]
16. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
[TBL] [Abstract][Full Text] [Related]
17. Poliomyelitis in intraspinally inoculated poliovirus receptor transgenic mice.
Deatly AM; Coleman JW; McMullen G; McAuliffe JM; Jayarama V; Cupo A; Crowley JC; McWilliams T; Taffs RE
Virology; 1999 Mar; 255(2):221-7. PubMed ID: 10069947
[TBL] [Abstract][Full Text] [Related]
18. Neurovirulence of Sabin 1-derived polioviruses isolated from an immunodeficient patient with prolonged viral excretion.
Yoneyama T; Yoshida H; Shimizu H; Yoshii K; Nagata N; Kew O; Miyamura T
Dev Biol (Basel); 2001; 105():93-8. PubMed ID: 11763343
[TBL] [Abstract][Full Text] [Related]
19. Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II.
Murdin AD; Wimmer E
J Virol; 1989 Dec; 63(12):5251-7. PubMed ID: 2479772
[TBL] [Abstract][Full Text] [Related]
20. [Studies of purification, inactivity and immunogenicity of antigenically chimeric poliovirus].
Cai H; Dai C
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Oct; 15(5):349-53. PubMed ID: 8168218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
